Advanced Filters
noise

vaccines Clinical Trials

A listing of vaccines medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 520 clinical trials
K Katja Gümüs, Dr. med

PANHPVAX, Study of a New HPV Vaccine in Healthy Volunteers

First-in-human, phase I, single-center, open-label, dose-escalation trial in healthy volunteers. Investigation of safety and tolerability of ascending doses of PANHPVAX, a vaccine against human papilloma L2 antigens formulated with cdA (adjuvant) as compared to the formulation without cdA.

18 - 45 years of age All Phase N/A
L Li

Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma

The therapeutic options for HCC include hepatectomy, liver transplantation, local ablation therapy, transarterial chemoembolization (TACE), radiotherapy, and systemic therapy. However, as early-stage HCC often presents with no obvious symptoms or atypical clinical manifestations, over 80% of patients are diagnosed at an advanced stage, losing the opportunity for surgical resection and …

18 years of age All Phase 1
W Weidong Han, Ph.D

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

This is a pilot clinical trial for subjects with local advanced/metastatic solid tumors or relapsed/refractory (R/R) lymphomas to determine the safety, efficacy and immune response of autologous EphA2-targeting CAR-DC vaccine loaded with TP53 mutant peptide (TP53-EphA-2-CAR-DC) in combination with ICIs. It aims to: assess the safety and antitumor effects of …

18 - 75 years of age All Phase 1
S Silvia Romano

Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)

Multiple sclerosis (MS) witnessed relevant therapeutic progress in the last decade. Following the extraordinary progress in the treatment of relapsing-remitting (RR) multiple sclerosis (MS), two major unmet needs remain to be addressed by translational research in this field: progressive MS and the "dream" of a world free of MS. As …

18 years of age All Phase 2

Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with melanoma and colorectal, gastric, ovarian, breast, lung …

18 years of age All Phase 1/2
Y Yu-Wen Zhou

Tumor Antigen-sensitized DC Vaccine for Colorectal Cancer Liver Metastases

The aim of this study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of R0 excision Colorectal Cancer Liver Metastases.

18 - 75 years of age All Phase 1
S Study Coordinator

Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults

This Phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of PepGNP-COVID19, a synthetic nanoparticle-based, T cell-priming peptide vaccine against SARS-CoV-2, when administered as a booster dose in healthy adults. PepGNP-COVID19 is designed to induce broad and durable T cell-mediated immune responses by delivering conserved SARS-CoV-2 peptides covalently …

18 - 64 years of age All Phase 1
A Arnaud Didierlaurent, Phd

Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients

The purpose of this study is to provide evidence as to whether RZV is immunogenic with an acceptable safety profile in Multiple Sclerosis patients on anti-CD20 treatment.

18 - 60 years of age All Phase 4
D Damayanti Tinduh, MD

UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)

The goal of this open-label clinical trial is to evaluate the safety and immunogenicity of INAVAC (Vaksin Merah Putih - UNAIR SARS-CoV-2 (Vero Cell Inactivated)) Vaccine as Homologue Booster in Adult Subjects in Indonesia. The main question it aims to answer is: "To evaluate the humoral immunogenicity profile at 28 …

18 years of age All Phase N/A
X Xingchen Peng, Ph.D

PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.

Evaluating the Safety and Efficacy of PD-1 mRNA LNP Vaccine Therapy in Patients with Primary Hepatocellular Carcinoma Who Have Failed Advanced Standard Therapy

18 - 70 years of age All Phase 1/2

Simplify language using AI